Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polvac ILIT for Grass Pollen Allergy
NCT05297760Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Feb 2022
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Polvac Grass+Rye in allergic rhinitis (AR), allergic asthma, sponsored by University of Zurich. Started Feb 2022; status: completed.
02
Drugs
Polvac Grass+Rye
03
Conditions
allergic rhinitis (AR)allergic asthma
Beyond the preview
Go deeper on NCT05297760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297760.